Department of Obstetrics and Gynecology, Louisiana State University Medical Center, New Orleans, Lousiana, 70112, USA
A recent conference reiterates the need for better screening and the development of an HPV vaccine.
REFERENCES
National Institutes of Health, Consensus Development Conference Statement. Cervical Cancer. April 1−3, 1996.
Parker, S.L., Tong, T., Bolden, S. & Wingo, P.A. Cancer statistics, 1996. CA — A Cancer J. Clinicians46, 5−27 (1996). | ChemPort |
Hayward, R.A. et al. Who gets screened for cervical and breast cancer? Results from a new national survey. Arch. Intern. Med.148, 1177−1181 (1988). | Article | PubMed | ISI | ChemPort |
Mandelblatt, J. et al. Gynecological care of elderly women: Another look at Papanicolaou smear testing. JAMA256, 367−371 (1986). | Article | PubMed | ISI | ChemPort |
Lehtinen, M. et al Serologically diagnoised infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: Nested case-control study. Br. Med. J.2, 537−539 (1996).
Prokopczyk, B. et al. Identification of tobacco-specific carcinogens in the cervical mucus of smokers and nonsmokers. Proc. Am. Assoc. Cancer Res.37, Abstr. 100 (1996).
Borysiewicz, L.K. et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet347, 1523−1527 (1996). | Article | PubMed | ISI | ChemPort |
Suzich, J.A. et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA92, 11553−11557 (1995). | PubMed | ChemPort |
